|Day's Range||2.6500 - 2.6500|
We'd be surprised if Henry Schein, Inc. (NASDAQ:HSIC) shareholders haven't noticed that an insider, Paul Brons...
"We continue to make progress in growing organically with a focus on sales of higher-margin products while making strategic investments to supplement growth in the years ahead."
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Henry Schein, Inc. (HSIC) reminds its customers in California that the Henry Schein Disaster Relief Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by the ongoing fires. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Members from 7 a.m. to 5 p.m. Central Time.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein, Inc. (HSIC), the world's largest provider of health care products and services to office-based dental and medical practitioners, announced today that its Board of Directors has authorized the repurchase of up to $400 million of shares of the Company's common stock. The Company had approximately 147 million shares outstanding as of October 30, 2019. This new authorization represents approximately 4.0 percent of shares outstanding at the current stock price.
The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.
Henry Schein, Inc. , the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the Credit Suisse 2019 Healthcare Conference at The Phoenician in Scottsdale, Arizona, on Tuesday, November 12, 2019, at 9:10 a.m.
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat third quarter 2019 view are likely to have contributed to Stryker's (SYK) Q3 earnings.
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find write-ups about an individual hedge fund's trades on numerous financial […]
Henry Schein, Inc. , the world's largest provider of health care products and services to office-based dental and medical practitioners, announced today that it will release its third quarter 2019 financial results before the stock market opens on Tuesday, November 5, 2019, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m.
Four large drug companies could resume talks on Tuesday to try to reach a $48 billion settlement of all opioid litigation against them, after agreeing with two Ohio counties to a $260 million deal to avert the first federal trial over their role in the U.S. opioid epidemic. Drug distributors AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp and drugmaker Teva Pharmaceutical Industries Ltd agreed to the deal that removed the immediate threat of a trial that was to begin on Monday in Cleveland. The parties could resume talks as soon as Tuesday aimed at a broader settlement of thousands of opioid lawsuits brought by states and local governments, according to Paul Hanly, an attorney for the towns and counties.
Henry Schein, Inc. (HSIC) announced today that the plaintiff has agreed to dismiss the Company with prejudice as a defendant in the opioid litigation involving Summit County, Ohio, presently before the U.S. District Court for the Northern District of Ohio. “The opioid crisis is a terrible national tragedy, and all segments of society need to come together to address the crisis,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein, Inc. “We look forward to playing a constructive role in helping to advance solutions that put an end to opioid addiction.
A landmark trial over the U.S. opioid epidemic is on track to begin on Monday after drug companies and local governments failed to agree on a settlement on Friday that had been expected to be valued at around $50 billion. Top executives of the largest U.S. drug distributors and drugmaker Teva Pharmaceutical Industries Ltd left a Cleveland courthouse on Friday and lawyers for states and thousands of local governments said there was no agreement. Paul Hanly, a lawyer for local governments that brought the bulk of the thousands of lawsuits stemming from the addiction crisis, said his team "fully expect" a trial to begin Monday.
An administrative law judge at the Federal Trade Commission has ruled that Benco Dental Supply Co and Patterson Companies Inc violated antitrust law by refusing to compete for the business of buying groups but dismissed a complaint against a third company, Henry Schein Inc, the agency said on Wednesday. The FTC had accused the three companies, the three largest U.S. full-service distributors of dental supplies ranging from chairs to cement to gloves, of violating antitrust law in February 2018. Judge Michael Chappell said in a decision dated Tuesday that the FTC "has shown that there was an agreement between Benco and Patterson to refuse to offer discounted prices or otherwise negotiate with buying groups.
Henry Schein, Inc. (HSIC) issued the following statement in response to a ruling released today by D. Michael Chappell, the Chief Administrative Law Judge of the U.S. Federal Trade Commission (link to decision), who dismissed claims that Henry Schein conspired with competitors to avoid providing discounts to, or to otherwise serve, buying groups representing dental practitioners. Henry Schein, Inc. (HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 19,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes.
Henry Schein, Inc. (HSIC) announced today that Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, received the National Network for Oral Health Access (NNOHA) President’s Award for his support of NNOHA as well as his personal, professional, and humanitarian accomplishments. Under Mr. Bergman’s leadership, Henry Schein played a pivotal role in helping to develop the organization during its inception in 1991. Mr. Bergman has continued to be a thought leader for inclusive health by recognizing the importance of NNOHA at its founding and supporting its goal of strengthening and expanding the nation’s oral health safety-net system.